41b25e1d-b18b-427f-906c-b16f29056775
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- E2F_TARGETS+0.400
- G2M_CHECKPOINT+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- COMPLEMENT+0.200
- IL2_STAT5_SIGNALING+0.200
- INFLAMMATORY_RESPONSE+0.200
- PI3K_AKT_MTOR_SIGNALING+0.200
- INTERFERON_ALPHA_RESPONSE+0.100
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.500
- ADIPOGENESIS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- FATTY_ACID_METABOLISM-0.400
- NOTCH_SIGNALING-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- PROTEIN_SECRETION-0.400
- GLYCOLYSIS-0.300
- HEDGEHOG_SIGNALING-0.300
- MYC_TARGETS_V2-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR5088892 | — | — | 0.893 |
| 2 | SRR5088835 | — | — | 0.881 |
| 3 | SRR5088834 | — | — | 0.865 |
| 4 | SRR6013475 | — | cohortMD2 | 0.837 |
| 5 | TCGA-85-A4PA-01A-11R-A24Z-07 | — | cohortMD2 | 0.837 |
| 6 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.817 |
| 7 | 6d7694d5-8582-466f-8072-df47dc10d780 | — | — | 0.807 |
| 8 | SRR10842377 | — | — | 0.804 |
| 9 | s0095135 | — | — | 0.800 |
| 10 | C3N-02922 | — | cohortMD2 | 0.797 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |